3-氨基吡嗪-2-羧酸乙酯 | 36526-32-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 3-氨基吡嗪-2-羧酸乙酯
• 英文名称: ethyl 3-amino[2,3-b]pyrazine-2-carboxylate
• 英文别名: 3-amino-pyrazine-2-carboxylic acid ethyl ester；ethyl 3-amino-2-pyrazinecarboxylate；ethyl 3-aminopyrazine-2-carboxylate；3-Aminopyrazin-2-carbonsaeureethylester
• CAS: 36526-32-6
• 化学式: C₇H₉N₃O₂
• mdl: MFCD07366530
• 分子量: 167.167
• InChiKey: IVPKIZXZEISSOJ-UHFFFAOYSA-N

物化性质

• 熔点：
  170 °C (sublm)(Press: 12 Torr)
• 沸点：
  310.6±37.0 °C(Predicted)
• 密度：
  1.261±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  78.1
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  3-氨基吡嗪-2-羧酸乙酯 在 吡啶 、 sodium hydroxide 、 氨 作用下， 以 乙醇 为溶剂， 生成 2-(3-Trifluoromethylphenyl)-pteridin-4-one
  参考文献：
  名称：

  Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors

  摘要：

  Screening of a focused library of TGF beta kinase inhibitors in the cellular HCV replicon model with luciferase read out yielded a number of low micromolar HCV inhibitors. Medicinal chemistry driven optimization resulted in the discovery of 4-[2-(5-bromo-2-fluoro-phenyl)pteridin-4-ylamino]-N-[3-(2-oxopyrrolidin-1-yl)propyl]nicotinamide 36 with a replicon EC50 of 64 nM, associated with a selective kinase inhibitory profile for human JNK kinases 2 and 3 as well as VEGFR-1, 2, and 3 kinases. Moreover, 36 showed an advantageous PK profile in mice. Experiments performed using different replicon constructs suggest that this series of kinase inhibitors might mediate their effect through the HCV non-structural protein 5A (NS5A). (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.046
• 作为产物：
  描述：

  Ethyl 2-amidino-2-aminoacetate dihydrochloride 以22%的产率得到
  参考文献：
  名称：

  KEIR W. F.; MACLENNAN A. H.; WOOD H. C. S., J. CHEM. SOC. PERKIN TRANS., PART 1, 1978, NO 9, 1002-1006,

  摘要：

  DOI：

文献信息

• Synthesis of imidazo[1,2-a]pyrazine derivatives with uterine-relaxing, antibronchospastic, and cardiac-stimulating properties
  作者：Claire Sablayrolles、Jean Claude Milhavet、Eliane Rechenq、Jean Pierre Chapat、Gerard H. Cros、Maurice Boucard、Jean J. Serrano、John H. McNeill

  DOI：10.1021/jm00368a018

  日期：1984.2

  A series of imidazo[1,2-alpha]pyrazine derivatives was synthesized by condensation of alpha-halogenocarbonyl compounds and aminopyrazines. Various compounds resulted from competitive reactions or reagent isomerization and demonstrated in vitro uterine-relaxing and in vivo antibronchospastic activities. On isolated atria, 5-bromoimidazo-[1,2-alpha]pyrazine showed positive chronotropic and inotropic

  通过α-卤代羰基化合物和氨基吡嗪的缩合合成了一系列咪唑并[1,2-α-吡嗪]衍生物。各种化合物是由竞争反应或试剂异构化产生的，并表现出体外子宫松弛和体内抗支气管痉挛活性。在分离的心房上，5-溴咪唑并[1,2-α]吡嗪表现出正变时性和变力性。后者与循环AMP组织浓度的增加有关。5-溴咪唑并[1,2-α]吡嗪对异丙肾上腺素的正性肌力作用的增强和普萘洛尔对5-溴咪唑并[1,2-α]吡嗪正性肌力的缺乏的缺乏提示磷酸二酯酶抑制性质。
• [EN] ANTIBACTERIAL PIPERIDINYL SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES<br/>[FR] 3,4-DIHYDRO-1H[1,8]NAPHTYRIDINONES SUBSTITUÉES PAR PIPÉRIDINYLE ANTIBACTÉRIENNES
  申请人：JANSSEN R & D IRELAND

  公开号：WO2013021052A1

  公开（公告）日：2013-02-14

  The present invention is related to novel compounds of formula (I) that inhibit the activity of the Fab1 enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.

  本发明涉及一种公式（I）的新化合物，它们抑制Fab1酶的活性，因此在治疗细菌感染方面具有用途。还涉及包括这些化合物的药物组合物，以及制备这些化合物的化学过程。
• [EN] NEW ANTIBACTERIAL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS ANTIBACTÉRIENS
  申请人：JANSSEN R & D IRELAND

  公开号：WO2014023815A1

  公开（公告）日：2014-02-13

  The present invention is related to novel compounds of formula (I) that may inhibit the activity of the FabI enzyme, and which are useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.

  本发明涉及一种可能抑制FabI酶活性的化合物（I）的新化合物，这些化合物在治疗细菌感染中很有用。还涉及包含这些化合物的药物组合物，以及制备这些化合物的化学过程。
• Antibacterial homopiperidinyl substituted 3,4 dihydro 1H[1,8]naphthyridinones
  申请人：Janssen R&D Ireland

  公开号：US20140171418A1

  公开（公告）日：2014-06-19

  The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.

  本发明涉及一种具有以下化学式（I）的新化合物，其抑制FabI酶的活性，因此在治疗细菌感染方面具有用处。还涉及包含这些化合物的药物组合物，以及制备这些化合物的化学过程。
• [EN] ANTIBACTERIAL HOMOPIPERIDINYL SUBSTITUTED 3,4 DIHYDRO 1H [1,8]NAPHTHYRIDINONES<br/>[FR] 3,4-DIHYDRO-1H[1,8]NAPHTYRIDINONES SUBSTITUÉES PAR HOMOPIPÉRIDINYLE ANTIBACTÉRIENNES
  申请人：JANSSEN R & D IRELAND

  公开号：WO2013021051A1

  公开（公告）日：2013-02-14

  The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.

  本发明涉及一种化合物的新颖结构（I）的公式，它抑制FabI酶的活性，因此在治疗细菌感染方面非常有用。还涉及包含这些化合物的药物组合物，以及制备这些化合物的化学过程。